



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Amubarvimab

Cat. No.:	HY-P99435
CAS No.:	2509447-07-6
Target:	SARS-CoV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a K_D of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants ^{[1][2]} .
In Vitro	Amubarvimab shows specific activity against wild-type SARS-CoV-2 and no cross-reactivity against other coronaviruses ^[1] . Amubarvimab binds to two regions spanning amino acids 453-505 in the receptor-binding motif (RBM) and amino acids residues 403-421 in the core region of RBD ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Amubarvimab (10-50 mg/kg; i.p.) in combination with romlusevimab significantly decreases viral load in the lungs, and reduces lung pathology in a Syrian golden hamster model of SARS-CoV-2 infection ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Ji Y, et, al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. *Front Immunol.* 2022 Sep 14;13:980435.

[2]. Hoy SM. Amubarvimab/Romlusevimab: First Approval. *Drug.* 2022 Aug;82(12):1327-1331.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA